Pharma R&D capitalization boundary

Pharma R&D spend is often the single largest expense line, and premature capitalization can materially inflate reported assets and equity while masking the true cash burn and risk profile of drug candidates from investors and lenders; conversely, an overly rigid blanket expensing policy can understate assets for the rare cases where development criteria are genuinely met.

At which clinical trial phase does management believe technical and regulatory success becomes probable for this specific candidate, and is that judgment supported by objective evidence such as positive Phase III results or filing acceptance, rather than optimism about avoiding an expense? Can development-phase costs be reliably attributed to a specific candidate rather than shared general research activity? Is there a documented, consistently applied policy for the phase at which capitalization begins, given the high historical attrition rate of pharma candidates?

1) Classify spend by phase: discovery, preclinical, and clinical Phase I/II are, for virtually all pharma candidates, research and must be expensed as incurred given the high attrition risk. 2) At each phase transition, assess objectively (not based on management optimism) whether all IAS 38 development criteria are simultaneously met: technical feasibility, intent and ability to complete/use or sell, probable future economic benefit, resource availability, reliable cost measurement. 3) For most drug candidates this bundle of criteria is only realistically met after positive Phase III results and, often, regulatory filing acceptance, given approval uncertainty before that point. 4) Where capitalization is concluded, capitalize only costs incurred after the criteria are met, do not capitalize retrospectively. 5) Document the conclusion candidate-by-candidate with objective evidence (trial results, regulatory correspondence), not a company-wide capitalization trigger point. 6) Continue to test any capitalized development costs for impairment if trial or regulatory setbacks occur.

Where capitalization is justified, measure at directly attributable development cost only (trial-specific costs, directly engaged staff time, directly attributable third-party fees); do not include an allocation of general R&D overhead unless it is directly attributable and reliably measurable to the specific candidate. Once capitalized, the asset is not amortized until the product is available for use/sale, but is tested for impairment at each reporting date and whenever a trial or regulatory setback occurs.

Disclose the accounting policy for R&D costs and the point at which the research/development boundary is assessed as crossed, if any; disclose the amount of R&D expensed in the period by major program/phase where material; disclose the judgment applied in concluding capitalization criteria were met for any capitalized amounts; disclose impairment charges on capitalized development costs following trial or regulatory setbacks.

• Capitalizing Phase II or even Phase I trial costs based on management optimism rather than objective evidence of probable success
• expensing genuinely qualifying late-stage development costs due to an overly conservative blanket policy without company-specific/candidate-specific analysis
• capitalizing an allocation of general corporate R&
• D overhead rather than only directly attributable costs
• failing to impair capitalized development costs promptly when a later-stage trial fails or regulatory approval is denied
• using the same capitalization trigger point across all candidates regardless of differing risk and evidence profiles.